These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8907275)

  • 21. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P; Amadori S; Calabretta B; Mandelli F
    Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
    Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism.
    Vaerman JL; Lammineur C; Moureau P; Lewalle P; Deldime F; Blumenfeld M; Martiat P
    Blood; 1995 Nov; 86(10):3891-6. PubMed ID: 7579358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
    Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
    J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides.
    Tari AM; Andreeff M; Kleine HD; Lopez-Berestein G
    J Mol Med (Berl); 1996 Oct; 74(10):623-8. PubMed ID: 8912183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
    Lin H; Monaco G; Sun T; Ling X; Stephens C; Xie S; Belmont J; Arlinghaus R
    Oncogene; 2005 May; 24(20):3246-56. PubMed ID: 15735695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.
    Pigneux A; Mahon FX; Jazwiec B; Pigeonnier V; Ripoche J; Reiffers J
    Leuk Lymphoma; 2000 Feb; 36(5-6):569-78. PubMed ID: 10784402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
    Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
    Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
    Clark RE
    Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.
    Schwartz GN; Liu YQ; Tisdale J; Walshe K; Fowler D; Gress R; Bergan RC
    Antisense Nucleic Acid Drug Dev; 1998 Aug; 8(4):329-39. PubMed ID: 9743470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
    Skorski T; Nieborowska-Skorska M; Campbell K; Iozzo RV; Zon G; Darzynkiewicz Z; Calabretta B
    J Exp Med; 1995 Dec; 182(6):1645-53. PubMed ID: 7500009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides.
    Bergan RC; Kyle E; Connell Y; Neckers L
    Antisense Res Dev; 1995; 5(1):33-8. PubMed ID: 7542047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p120 GAP requirement in normal and malignant human hematopoiesis.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak M; Szczylik C; Zon G; Arlinghaus RB; Gewirtz A; Perussia B; Calabretta B
    J Exp Med; 1993 Dec; 178(6):1923-33. PubMed ID: 8245773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
    Chu S; McDonald T; Bhatia R
    Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circular antisense oligonucleotides inhibit growth of chronic myeloid leukemia cells.
    Rowley PT; Kosciolek BA; Kool ET
    Mol Med; 1999 Oct; 5(10):693-700. PubMed ID: 10602778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morpholino Oligo Antisense efficiently suppresses BCR/ABL and cell proliferation in CML: specific inhibition of BCR-ABL gene expression by Morpholino Oligo Antisense in BCR-ABL(+) cells.
    Haririan M; Kaviani S; Soleimani M; Ghaemi SR; Delalat B; Atashi A
    Hematology; 2012 Jan; 17(1):28-34. PubMed ID: 22549445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
    O'Brien SG; Kirkland MA; Melo JV; Rao MH; Davidson RJ; McDonald C; Goldman JM
    Leukemia; 1994 Dec; 8(12):2156-62. PubMed ID: 7808004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.